Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) ...

A new study published in the Chest Journal showed that Dupilumab helps individuals with type 2 inflammation and chronic ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to support US regulatory resubmission by year-end; if ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to ...

Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...

Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...

Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...

More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...